Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
Why BeiGene's Shares Jumped on Friday
01:17pm, Friday, 17'th Sep 2021
The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
12:59pm, Thursday, 16'th Sep 2021
The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
08:40am, Wednesday, 15'th Sep 2021
The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-C
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA
01:28pm, Monday, 13'th Sep 2021
The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
12:00am, Monday, 13'th Sep 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable m
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
06:05pm, Sunday, 12'th Sep 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines wo
Why BeiGene Stock Is Soaring This Week
04:30pm, Thursday, 02'nd Sep 2021
The company won another FDA approval for blood cancer drug Brukinsa.
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion
11:24am, Thursday, 02'nd Sep 2021
The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.
BeiGene's Brukinsa Scores FDA Approval For Rare Blood Cancer Indication
09:37am, Thursday, 02'nd Sep 2021
The FDA has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström's macroglobulinemia (WM). Brukinsa WM approval is the second therapy ap
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's Macroglobulinemia
05:33pm, Wednesday, 01'st Sep 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE--U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's Macroglobulinemia
Tonight! Novartis, Roche, BeiGene, Others Discuss Global Fight Against Cancer In Covid Era
11:46am, Friday, 27'th Aug 2021
Against that backdrop, Forbes China will hold the second “Forbes China Healthcare Summit” at 8pm ET tonight (8am on August 28 in China).
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
07:00pm, Sunday, 22'nd Aug 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines wo
This Is the Only Chinese Stock I Would Buy Right Now
06:31am, Friday, 20'th Aug 2021
A diamond in the rough is a pretty rare find, especially among Chinese stocks.
BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide,
BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China
10:09am, Tuesday, 17'th Aug 2021
The China National Medical Products Administration (NMPA) granted conditional approval for BeiGene Ltd (NASDAQ: BGNE) - EUSA Pharma's (UK) Qarziba (dinutuximab beta) in high-risk neuroblastoma
